CD8A and neoplasm: As mentioned before, the levels of EZH2 negatively correlated with intratumoral CD8+ T cells in ovarian cancer, so EZH2 inhibitor could increase effector T cell tumor infiltration, slowed down tumor progression, and synergistically improved the efficacy of adoptive T cell therapy [45].